Richard T. Silver MD Myeloproliferative Neoplasms Center

You are here

Featured Publications

Found 16 results
2017
Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J et al..  2017.  A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.. Leukemia.
Silver RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, Orazi A, Hassane DC, Tam W, Cross NCP.  2017.  The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.. Cancer. 123(14):2680-2687.
Kvasnicka HMichael, Orazi A, Thiele J, Barosi G, Bueso-Ramos CE, Vannucchi AM, Hasserjian RP, Kiladjian J-J, Gianelli U, Silver R et al..  2017.  European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.. Am J Hematol. 92(10):1062-1067.
Margolskee E, Krichevsky S, Orazi A, Silver RT.  2017.  Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.. Haematologica. 102(3):e97-e99.
Silver RT, Krichevsky S, Gjoni S, Cross NCP.  2017.  Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera.. Leuk Lymphoma. 58(11):2768-2769.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian J-J, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC et al..  2017.  Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.. Lancet Haematol. 4(7):e317-e324.
Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M et al..  2017.  Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.. J Hematol Oncol. 10(1):55.
2016
Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E et al..  2016.  Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.. Clin Lymphoma Myeloma Leuk. 16(5):297-303.
Xu Z, McGowan-Jordan J.  2016.  CML with complex chromosome rearrangements and dysplastic megakaryocytes.. Blood. 128(4):604.
Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R et al..  2016.  Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.. J Natl Cancer Inst. 108(7)
Hehlmann R, Saußele S, Voskanyan A, Silver RT.  2016.  Management of CML-blast crisis.. Best Pract Res Clin Haematol. 29(3):295-307.
Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian J-J, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL et al..  2016.  Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.. Leukemia. 30(5):1018-24.
Silver RT, Hasselbalch HCarl.  2016.  Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials.. Hematology. 21(7):387-91.
Senkevitch E, Durum S.  2016.  The promise of Janus kinase inhibitors in the treatment of hematological malignancies.. Cytokine.
Jones GH, Carrier MA, Silver RT, Kantarjian H.  2016.  Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.. Blood. 127(11):1398-402.
2008
Robins EB, Niazi M.  2008.  Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies.. Pediatr Blood Cancer. 50(4):859-61.